OBJECTIVES The goal of this study was to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of escalating ticagrelor loading dose (LD) regimens in primary percutaneous coronary intervention (PPCI).
T icagrelor is a first-in-class cyclopentyltriazolopyrimidine, which reversibly and directly (without being metabolized) inhibits the platelet P2Y 12 receptor; approximately 30% of ticagrelorinduced platelet inhibition derives from a metabolite generated through cytochrome P450 3A4 metabolism (1, 2) . Compared with clopidogrel, ticagrelor has more prompt and potent antiplatelet effects and reduces, to a greater extent, atherothrombotic events including cardiovascular mortality in patients with acute coronary syndrome (3) (4) (5) .
Importantly, the benefits of ticagrelor were shown to be consistent across several subgroups, comprising patients with STsegment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) (5, 6) . Recently, pharmacodynamic (PD) studies assessing oral P2Y 12 inhibitors, including ticagrelor, have shown a delay in platelet inhibitory effects in STEMI patients undergoing PPCI (7) (8) (9) . In turn, a considerable number of patients persist with inadequate platelet inhibition in the early hours after loading dose (LD) administration, suggesting the potential need for higher dosing regimens (8, 9) . Although pharmacokinetic (PK) studies conducted in healthy volunteers have shown that peak plasma concentrations of ticagrelor are dose-dependent (2) , to date there are no studies that have comprehensively investigated both the PK and PD effects of higher ticagrelor LD in STEMI patients undergoing PPCI. Blood samples for PK and PD analysis were collected at baseline (before PPCI) and at a total of 6 time points following study drug administration: 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h after LD (with a AE 10% time window). A flow diagram of the study design is presented in Figure 1 . In-hospital adverse events, including ischemic events, bleeding, bradyarrhythmias, and dyspnea, defined according to previously reported criteria in the PLATO (PLATelet inhibition and patient Outcomes) trial (6) , were recorded. The study complied with the Declaration of Helsinki, was approved by the Western Institutional Review Board, and all patients gave their written informed consent.
PK AND PD ASSESSMENTS. PK assessments included determination of plasma concentration of ticagrelor and its active metabolite (AR-C124910XX), as previously described (2) . Time for the maximal plasma concentration (T max ), maximal observed plasma concentration (C max ), and the area under the plasma concentration versus time curve from time 0 to the last measurable concentration (AUC 0-t ) were calculated. Dose-normalized C max and AUC 0-t were also calculated to assess the effects of morphine. Franchi et al.
PD assessments included the VerifyNow P2Y12 (Accriva Diagnostics, San Diego, California) and wholeblood vasodilator-stimulated phosphoprotein (VASP) assays (Diagnostica Stago, Parsippany, New Jersey), which were performed according to the manufacturer's instructions, as previously described (4,10).
The VerifyNow P2Y12 assay reports results in P2Y 12 reaction units (PRU). The VASP assay was used to determine the platelet reactivity index (PRI) according to standard protocols (4,10). High on-treatment platelet reactivity (HPR) was defined as a PRU >208 or a PRI >50% (10). Figure 1 .
Franchi et al. Table 1 and were similar between groups, except for the use of morphine, which was higher in patients in the 360-mg LD group (p ¼ 0.005).
S E P T E M B
One patient in the 270-mg group had an ischemic stroke. The rate of any in-hospital bleeding was 7.7%. Franchi et al. Error bars indicate standard error. LD ¼ loading dose. The overall rate of HPR at 4 h was 18.6% and was numerically higher in the 360-mg group (28.6%) compared with the 180-mg (20%) and 270-mg groups (7.1%). At 8 and 24 h after LD, the rates of HPR were lower (ranging from 0% to 14.3%) and overall similar among dosing regimens ( Figure 4B) . After multivariable analysis, we found no independent predictors of HPR assessed by VASP. The rates of patients experiencing HPR with both assays were approximately 66%, 40%, 30%, 7%, 2.5%, and 0% at 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h after LD, respectively. PHARMACOKINETIC ASSESSMENT. Following ticagrelor LD administration, ticagrelor absorption was delayed irrespective of dose, with mean ticagrelor T max ranging from 3.9 h in the 180-mg group to 7.1 h in the 360-mg group. Accordingly, generation of the active metabolite AR-C124910XX was also delayed for all 3 ticagrelor LD regimens tested, with a mean T max of 6.3 to 9.1 h ( Table 2 ). Exposure to ticagrelor and AR-C124910XX, measured as C max and AUC 0-t , increased only with the dosing regimen escalating from 180 mg to 270 mg, whereas merely a minimal increase was observed when escalating from 270 mg to 360 mg ( Table 2 ).
The mean plasma concentrations of ticagrelor were higher in the 270-mg group at 30 min and 1 h following LD, whereas at 2 h, the highest mean plasma con- 
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not receiving morphine, although these differences were not significant ( Figure 7B ). Parallel findings were observed with VASP-PRI (data not shown). After multivariable analysis, morphine use was not found to be an independent predictor of HPR.
The PK assessment showed lower mean plasma concentrations of both ticagrelor and AR-C124910XX during the first 2 h following LD administration in morphine-treated patients ( Figures 7C and 7D) .
Accordingly, in patients receiving morphine, ticagrelor absorption was slightly delayed (mean T max 5.6 vs. 4.9 h) and formation of the active metabolite AR-C124910XX was slower (mean T max 8.1 vs. 6.8 h) compared with patients not receiving morphine.
Dose-normalized exposure to ticagrelor and AR-C124910XX was lower in patients who received morphine (Online Table 1 ).
DISCUSSION
The present study is the first to investigate both the 
Ticagrelor Dosing and Antiplatelet Effects activity of the gastrointestinal tract, nausea, and vomiting, which in turn can lead to impaired intestinal absorption and hepatic metabolism (9, 13) . Our study demonstrated that this delay in the antiplatelet effect of ticagrelor is mainly attributed to an altered PK profile ("drug exposure"), with impaired absorption in the early hours after drug administration, and not to platelet dysfunction ("drug response"). This is further demonstrated by the presence of extremely low plasma concentrations of ticagrelor and AR-C124910XX in the first 2 h after LD in patients with HPR. In our study, we found that the only independent predictor of HPR was the use of ACE inhibitors/ ARBs, which was independently associated with the absence of HPR at 2 h assessed by VerifyNow. However, because this association was shown only with 1 assay and only at 2 h, these observations are most likely due to play of chance.
Because ticagrelor is a direct-acting agent that has a dose-dependent PK profile in healthy volunteers (2), the use of higher LD regimens has been advocated in STEMI patients undergoing PPCI. In a nonrandomized PD comparison of STEMI patients undergoing PPCI, Alexopoulos et al. (14) showed that a high LD of ticagrelor (360 mg) was not Although we showed that a 270-mg LD achieved higher platelet inhibition in the first hour after LD, significant differences were only observed with 1 PD assay. Surprisingly, in the first 2 h following LD, the lowest antiplatelet effect was observed with the 360-mg LD. These findings were paralleled by PK profiles that showed a prolonged T max and no meaningful increase in drug exposure compared with a 270-mg LD. This may be in part attributed to the higher use of morphine in this group. In fact, morphine is known to inhibit gastric emptying and oral-cecal transit time, leading to delayed absorption and potentially decreasing peak plasma levels of orally administered drugs (16) . In a study of healthy volunteers, morphine has shown to also impair clopidogrel absorption and reduce plasma levels of its active metabolite, which translated into delayed and hampered PD effects (17) . Moreover, a post-hoc anal- Franchi et al.
potential mechanistic insights on why the trial did not meet its primary endpoint. However, a significant interaction between morphine use and the time of ticagrelor administration was observed on pre-PCI coronary reperfusion, which may have affected the overall trial results (19) . Consistent with these findings, in our study, morphine significantly altered the PK profiles of ticagrelor resulting in delayed drug absorption and lower PD effects in the early hours following LD. However, the above results need to be interpreted as hypothesis generating since these were post-hoc assessments conducted in a subgroup.
Moreover, in our study, morphine use was not found to be an independent predictor of HPR. Indeed, specifically designed randomized prospective investigations exploring the role of morphine are needed to better clarify its effect on the PK/PD profiles of ticagrelor.
The findings that a considerable number of STEMI patients have levels of platelet reactivity above thresholds associated with thrombotic events even after doubling the LD regimen of ticagrelor, underscore the need for strategies aimed to achieve more optimal platelet inhibition particularly in the early hours after PPCI. The use of potent intravenous antiplatelet agents, prolonging bivalirudin infusion and crushing of oral antiplatelet tablets to facilitate gastrointestinal absorption may help overcome this issue (7, (20) (21) (22) (23) .
STUDY LIMITATIONS. Our study was not powered to assess safety or efficacy, which would require larger (9, 18, 19) . Further, all PD comparisons were adjusted for morphine use, and morphine was not an independent predictor of impaired drug response at multivariable analysis.
Importantly, the PD and PK profiles of ticagrelor were also compromised in patients not receiving morphine. However, we cannot rule out that a larger sample size would have resulted in a more homogenous distribution of morphine use and in different results about its influence on the PK and PD profiles of ticagrelor. Therefore, our study observations on morphine should be considered exploratory and hypothesis generating for dedicated trials. The sample size of our study was calculated according to published data available at the time of our study design (3, 8) . Subsequent studies have shown that the PD differences of increasing ticagrelor LD were actually lower, making our study underpowered (14) . Therefore, we cannot exclude that a larger population would have resulted in different study findings. 
WHAT IS NEW?
The impaired response to ticagrelor in the early hours after drug administration in patients undergoing primary percutaneous coronary intervention cannot be overcome by increasing loading dose regimens. This delay in the antiplatelet effect is mainly attributed to an altered pharmacokinetic profile ("drug exposure"), with reduced absorption in the early hours after drug administration.
WHAT IS NEXT? There is need for further studies aimed to identify strategies to achieve more optimal platelet inhibition in the early hours after primary percutaneous coronary intervention, such as the use of potent intravenous antiplatelet agents and crushing of oral antiplatelet tablets to facilitate gastrointestinal absorption.
Franchi et al.
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